Stocktoria

Immunovant, Inc. IMVT

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-05-14

Immunovant, Inc. statistics & valuation

Market cap$8.0B
P / B9.4×
Return on equity-59.3%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20192020202120222023202420252026
Operating margin (%)
20192020202120222023202420252026
Return on equity (%)
-389.70% -70.60% -27.40% -33.40% -58.20% -42.00% -58.50% -59.30% 20192020202120222023202420252026
Shares outstanding
38.6M 54.7M 98.0M 116.5M 130.3M 145.6M 170.1M 203.9M 20192020202120222023202420252026
Net debt ($)
20192020202120222023202420252026
Share buybacks ($)
20192020202120222023202420252026
Return on assets (%)
-206.80% -60.70% -26.00% -30.40% -52.00% -38.90% -53.30% -52.80% 20192020202120222023202420252026
Free cash flow margin (%)
20192020202120222023202420252026
Debt / equity (×)
20192020202120222023202420252026
EPS ($)
-$1.22 -$1.43 -$1.71 -$1.88 -$2.73 -$2.77 20192020202120222023202420252026

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on assets-52.8%-53.3%-38.9%-52.0%-30.4%-26.0%-60.7%-206.8%
Return on equity-59.3%-58.5%-42.0%-58.2%-33.4%-27.4%-70.6%-389.7%
Current ratio9.0911.1613.709.3411.5221.797.1241.87

Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.